Amarantus BioScience Holdings EBIT

The latest EBIT for AMBS is $-1.8M as of March 2023. That compares with $-13M in the prior-year period — up 86.4% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside Amarantus BioScience Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, AMBS's EBIT moved from $-13M to $-1.8M — a 86.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Amarantus BioScience Holdings's operating scale or balance-sheet position.

Against Healthcare companies, AMBS currently prints $-1.8M for EBIT, while the sector average sits near $130B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Amarantus BioScience Holdings's growth, margins, and balance sheet.

A EBIT figure of $-1.8M for AMBS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting AMBS's EBIT ($-1.8M), review year-over-year change from $-13M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.